T'gana pharma giants wary of US tariff impact

Since the Donald Trump administration is currently targeting only the branded and patented drugs, the pharma industry wants to treat this as an opportunity to step up trade negotiations with other countries, diversify export markets, and invest more heavily in complex generics and biosimilars.